GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction

GlaxoSmithKlineGlaxoSmithKline (GSK) announced that it will no longer pursue global approval (marketing authorisation) for the use of Avodart™ (dutasteride) to reduce the risk of prostate cancer. The Company will withdraw applications from regulatory review where procedures are ongoing and, in the limited number of countries where dutasteride is already indicated for use in prostate cancer risk reduction, GSK will work with regulatory agencies to remove this indication from the product's licence and support physicians to communicate appropriately to patients.

The prostate cancer risk reduction applications were based on findings from the Phase III REDUCE trial (REduction by DUtasteride of prostate Cancer Events) which were first presented at the American Urological Association Annual Meeting, April 2009 and subsequently published in the New England Journal of Medicine in 2010.(1)

As a result of GSK's continuing evaluation of available data, GSK began filing applications with regulatory agencies worldwide for the use of dutasteride to reduce the risk of prostate cancer from the end of 2009.

In January 2011, GSK received a Complete Response letter following a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee Meeting (ODAC) in December 2010, when the majority voted against a favourable risk/benefit profile for dutasteride for reduction in the risk of prostate cancer in men at risk for the disease. This was essentially due toquestions regarding the clinical significance of reducing the risk of low grade prostate cancer, and uncertainties surrounding the possible explanations for the increased number of cases of high grade tumours in men treated with 5-alpha reductase inhibitors (5ARIs) for prostate cancer risk reduction. Following similar feedback from Sweden, the Reference Member State in Europe, received in February 2011, GSK has now notified the Swedish MPA of its withdrawal from the regulatory review.

Regulatory filings were also made in other countries outside the US and EU resulting in a small number of countries approving the indication.

Overall, a combination of factors including the ongoing medical and scientific debate around the benefits and risks of 5ARIs for prostate cancer risk reduction, together with feedback from regulatory agencies has caused GSK to carefully consider its approach to the indication and subsequently withdraw ongoing applications for approval.

Dutasteride use in benign prostatic hyperplasia (BPH)
Dutasteride is approved in over 90 countries (as a monotherapy or in combination with tamsulosin) to treat the symptoms of BPH in men with an enlarged prostate and, in some countries, reduction in the risk of acute urinary retention (AUR) and BPH-related surgery.

GSK reviews the safety and performance of all its medicines on a continuous basis and is committed to further investigations to advance the understanding of the benefits and risks of dutasteride. To that end, dutasteride has been extensively studied in clinical trials involving 7,500 men with BPH and has an estimated 6.6 million patient-years of exposure. As a result of these evaluations, GSK believes that dutasteride for BPH continues to have a favourable risk/benefit profile.

As part of its continuing dialogue with regulatory agencies GSK is working with them to update the existing labels for all dutasteride-containing medicines*. The update for physicians and patients will include relevant safety information from the REDUCE study and will continue to emphasise the importance of regular PSA monitoring. GSK will also provide communications to physicians to facilitate awareness and understanding of any changes.

About dutasteride
Dutasteride is a dual 5-alpha reductase inhibitor for use to treat symptomatic BPH and reduction in the risk of AUR and BPH-related surgery.

* Labels for all dutasteride containing medicines will be updated, including Avodart™, known in some countries as Avolve™ or Avidart™, and Duodart™, known in some countries as Jalyn™ or Combodart™.

GlaxoSmithKline - one of the world’s leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

1. Andriole G, Bostwick D, Brawley O, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192-1202.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...